text
"['\nXII. 상세표\n1. 연결대상 종속회사 현황(상세)\n☞ 본문 위치로 이동\n(단위 : 천원)\n상호\n설립일\n주소\n주요사업\n최근사업연도말자산총액\n지배관계 근거\n주요종속회사 여부\n(주)힐리언스\n2005.07\n대한민국\n생활습관병예방연구\n31,160,612\xa0\n지배기업의종속기업\n-\nDAEWOONG PHARMACEUTICAL HONGKONG\n2013.07\n홍콩\n지주회사\n41,979,007\xa0\n지배기업의종속기업\n-\n요녕대웅제약유한공사\n2008.07\n중국\n의약품 제조 및 판매\n32,712,153\xa0\nDAEWOONG PHARMACEUTICAL HONGKONG의 종속기업\n-\nPT. Daewoong Pharmaceutical(Indonesia)Co.,Ltd.\n2005.12\n인도네시아\n의약품 판매\n2,386,331\xa0\n지배기업의종속기업\n-\nPT. DAEWOONG INFION\n2013.02\n인도네시아\n의약품 제조 및 판매\n10,168,101\xa0\nPT. Daewoong Pharmaceutical(Indonesia)Co.,Ltd.의 종속기업\n-\nDaewoong Pharma PHILIPPINES INC.\n2007.05\n필리핀\n의약품 판매\n2,610,449\xa0\n지배기업의종속기업\n-\nDaewoong Pharmaceutical(Thailand)Co.,Ltd.\n2007.07\n태국\n의약품 판매\n3,542,105\xa0\n지배기업의종속기업\n-\n한올바이오파마㈜\n1973.11.\n대한민국\n의약품 판매\n219,483,648\xa0\n지배기업의종속기업\n○(지배회사 자산총액의 10% 이상)\nHPI,INC.\n2007.08\n미국\nFDA임상시험 진행\n347,327\xa0\n한올바이오파마(주)의 종속기업\n-\n북경대웅위업의약과기유한공사\n2007.07\n중국\n의약품 연구\n4,193,618\xa0\n지배기업의종속기업\n-\nDaewoong Pharmaceutical India Pvt.,Ltd.\n2012.11\n인도\n의약품 연구\n849,678\xa0\n지배기업의종속기업\n-\nDaewoong America, Inc.\n2009.12\n미국\n의약품 연구\n97,102\xa0\n지배기업의종속기업\n-\nDaewoong Pharmaceutical(Japan)Co., Ltd.\n2017.03\n일본\n의약품 제조 및 판매\n7,671,649\xa0\n지배기업의종속기업\n-\n아피셀테라퓨틱스\n2020.01\n대한민국\n의약품 연구\n5,688,129\xa0\n지배기업의종속기업\n-\n아이엔테라퓨틱스\n2020.05\n대한민국\n의약품 연구\n2,125,940\xa0\n지배기업의종속기업\n-\nDaewoong innovation holdings\n2021.05\n미국\n의약품 연구\n590,201\n지배기업의종속기업\n-\nDaewoong Biologics Indonesia\n2021.09\n인도네시아\n의약품 제조 및 판매\n3,150,200\xa0\nPT. Daewoong Pharmaceutical(Indonesia)Co.,Ltd.의 종속기업\n-\n* 상기 최근사업연도말 자산총액은 2020년말 기준입니다.* Daewoong Innovation holdings 및 Daewoong Biologics indonesia의 자산총액은 당분기말 기준입니다.\n2. 계열회사 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2021년 09월 30일\n)\n(단위 : 사)\n상장여부\n회사수\n기업명\n법인등록번호\n상장\n3\n(주)대웅\n131111-0000271\n(주)대웅제약\n134811-0075342\n한올바이오파마(주)\n164111-0000397\n비상장\n33\n대웅바이오(주)\n134811-0172221\n(주)대웅생명과학\n210111-0013294\n(주)대웅경영개발원\n110111-0776463\n(주)산웅개발\n110111-0978671\n(주)대웅이엔지\n134811-0034421\n(주)팜팩\n134811-0048307\n(주)대웅개발\n131111-0083649\n(주)아이디에스앤트러스트\n110111-1234006\n㈜에이치알그룹\n110111-2041872\n㈜에스티에이치이솔루션\n110111-4326735\n(주)대웅테라퓨틱스\n135811-0360271\n(주)힐리언스\n110111-3265778\n다나아데이터㈜\n110111-6935790\n(주)엠디웰아이엔씨\n110111-3716854\n농업회사법인(주)대웅낙원\n141411-0009986\n(주)아피셀테라퓨틱스\n134511-0431912\n(주)아이엔테라퓨틱스\n134511-0459592\n(주)대웅펫\n110111-7040457\nDaewoong Pharma PHILIPPINES INC.\n-\n북경대웅위업의약과기유한공사\n-\nDaewoong Pharmaceutical(Thailand)Co.,Ltd\n-\nDaewoong America, Inc.\n-\nPT. Daewoong Pharmaceutical(Indonesia)Co.Ltd\n-\n사천대웅생물기술유한공사\n-\nDAEWOONG PHARMACEUTICAL HONGKONG\n-\nDaewoong Pharmaceutical India Pvt.,Ltd\n-\nDaewoong Pharmaceutical Japan Co., Ltd.\n-\nHPI,INC\n-\n요녕대웅제약유한공사\n-\nPT. DAEWOONG INFION\n-\nDaewoong Bio Indonesia\n-\nDaewoong Innovation Holdings\n-\nDaewoong Biologics Indonesia\n-\n* 지주회사 : (주)대웅* 자회사 : (주)대웅제약 외 12개사* 손자회사 : (주)한올바이오파마 외 6개사* 해외법인 : Daewoong Pharma PHILIPPINES INC. 외 14개사\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2021년 09월 30일\n)\n(단위 : 천원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n한올바이오파마(주)\n상장\n-\n인수\n116,111,366\n16,115,745\n31\n116,111,366\n-\n-\n-\n16,115,745\n31\n116,111,366\n219,483,648\n19,863,538\n힐리언스\xa0\n비상장\n-\n인수\n27,310,924\n2,753,300\n76\n14,434,620\n100,000\n1,185,600\n-1,426,312\n2,853,300\n79\n14,193,908\n31,160,612\n-2,964,072\nDaewoong Pharma PHILIPPINES, INC.\n비상장\n-\n설립\n260,539\n0\n100\n260,539\n-\n-\n-\n0\n100\n260,539\n2,610,449\n253,627\nDaewoong Pharmaceutical(Thailand)Co.,Ltd)\n비상장\n-\n설립\n205,389\n0\n100\n205,389\n-\n-\n-\n0\n100\n205,389\n3,542,105\n727,562\nPT. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA\xa0\n비상장\n-\n설립\n7,812,111\n0\n100\n7,812,111\n6,993,141\n6,993,141\n-\n6,993,141\n100\n14,805,252\n2,386,331\n-707,166\nDAEWOONG PHARMACEUTICAL HONGKONG\xa0\n비상장\n-\n설립\n17,660,725\n269,255,424\n90\n37,184,429\n-\n-\n-\n269,255,424\n90\n37,184,429\n41,979,007\n-14,814\n북경대웅위업의약과기유한공사\n비상장\n-\n설립\n9,152,033\n0\n100\n5,827,684\n-\n-\n-\n0\n100\n5,827,684\n4,193,618\n734,568\n바이오시네틱스\n비상장\n-\n사업관련\n2,000,000\n645,000\n18\n819,086\n-\n-\n-\n645,000\n18\n819,086\n2,139,099\n-1,473,558\n이피피미디어\n비상장\n-\n사업관련\n1,000,000\n100,000\n20\n0\n-\n-\n-\n100,000\n20\n0\n6,815,780\n-296,971\n엠디웰아이엔씨\n비상장\n-\n설립\n500,000\n100,000\n50\n500,000\n-\n-\n-\n100,000\n50\n500,000\n9,829,663\n1,669,222\nDaewoong America, Inc.\n비상장\n2009.12.30\n설립\n825,005\n0\n100\n83,286\n-\n-\n-\n0\n100\n83,286\n97,102\n84,033\nDaewoong Pharmaceutical India Pvt.,Ltd\xa0\n비상장\n-\n설립\n550,733\n0\n100\n550,733\n-\n-\n-\n0\n100\n550,733\n849,678\n225,637\nDAEWOONG PHARMACEUTICAL JAPAN CO.,LTD\n-\n2017.03.08\n설립\n555,621\n1,100\n100\n555,621\n-\n-\n-\n1,100\n100\n555,621\n7,671,649\n659,692\n건강한삶기술창업벤처PEF\xa0\n-\n2018.03.19\n설립\n2,500,000\n2,500,000,000\n50\n2,500,000\n-\n-\n-\n2,500,000,000\n50\n2,500,000\n4,658,995\n-145,967\n㈜다나아데이터\n비상장\n2018.11.23\n설립\n5,100,000\n102,000\n51\n5,100,000\n-\n-\n-\n102,000\n51\n5,100,000\n10,127,138\n139,274\nImmplacate, Inc.\n비상장\n2019.03.08\n사업관련\n1,125,970\n1,428,571\n20\n1,125,970\n-\n-\n-\n1,428,571\n20\n1,125,970\n26,949\n-187,662\n아피셀테라퓨틱스\n비상장\n2020.01.23\n설립\n1,960,780\n1,960,780\n54\n1,960,780\n1,577,528\n7,020,000\n-\n3,538,308\n82\n8,980,780\n5,688,129\n-1,174,712\n아이엔테라퓨틱스\n비상장\n2020.05.27\n설립\n3,118,330\n17,414,405\n100\n3,118,330\n-\n-\n-\n17,414,405\n100\n3,118,330\n2,125,940\n-2,566,132\nDaewoong Innovation Holdings\n-\n2021.07.14\n설립\n-\n-\n-\n-\n-\n572,550\n-\n0\n100\n572,550\n0\n0\nEvolus.INC(해외상장)(주3)\n-\n2021.03.23\n사업관련\n-\n-\n-\n-\n3,136,869\n57,099,225\n-28,776,629\n3,136,869\n6\n28,322,596\n209,068\n-163,013\n진켐 (주4)\n비상장\n-\n사업관련\n559,660\n41,932\n3\n475,551\n-\n-\n-\n41,932\n1\n475,551\n17,124,130\n-6,055,033\n바이오넷\xa0\n비상장\n2001.12.22\n사업관련\n1,207,646\n324,480\n3\n227,136\n-\n-\n-\n324,480\n3\n227,136\n15,420,980\n124,314\n큐어바이오\n비상장\n-\n사업관련\n217,377\n3,111\n2\n308,101\n-\n-\n-\n3,111\n1\n308,101\n11,886,803\n-2,895,288\n3D Matrix (해외상장)(주2)\n-\n-\n사업관련\n1,362,230\n320,000\n2\n974,980\n-\n-\n54,418\n320,000\n1\n1,029,398\n29,840\n-27,650\n카이페리온\n비상장\n2019.10.16\n단순투자\n1,000,020\n28,572\n3\n1,000,020\n-\n-\n-\n28,572\n3\n1,000,020\n5,018,113\n-1,224,456\nJTBC\xa0\n비상장\n-\n단순투자\n3,000,000\n600,000\n1\n166,800\n-\n-\n-\n600,000\n1\n166,800\n401,083,935\n-25,497,001\n향남제약공단\n비상장\n-\n단순투자\n217,879\n0\n-\n217,879\n-\n-\n-\n0\n-\n217,879\n0\n0\n자일자동차판매\n비상장\n-\n단순투자\n827,695\n0\n0\n200,098\n-\n-\n-\n0\n0\n200,098\n285,973,505\n19,763,288\n인벤티지랩\n비상장\n2020.04.28\n단순투자\n999,995\n83,326\n1\n999,995\n-\n-\n-\n83,326\n1\n999,995\n22,337,134\n-12,880,030\n입셀\n비상장\n2020.09.09\n단순투자\n2,000,002\n9,091\n9\n2,000,002\n-\n-\n-\n9,091\n9\n2,000,002\n58,101\n-114,828\n데일리 임파워링 바이오 헬스케어 펀드4호\n-\n2020.09.23\n단순투자\n1,000,000\n1,000\n7\n1,000,000\n-\n-\n501,613\n1,000\n7\n1,501,613\n15,235,722\n-70,585\n유안타 퀀텀점프 3호 투자조합\n-\n2021.09.10\n단순투자\n-\n-\n-\n-\n1,000\n1,000,000\n-\n1,000\n14\n1,000,000\n0\n0\n티온랩테라퓨틱스\n비상장\n2021.07.21\n단순투자\n-\n-\n-\n-\n97,109\n738,999\n-\n97,109\n15\n738,999\n0\n0\n서울의료정보연구소\n-\n2020.12.11\n단순투자\n200,063\n1,067\n6\n200,063\n-\n-\n-\n1,067\n6\n200,063\n297,475\n-310,550\nNurron\n-\n2021.09.10\n단순투자\n-\n-\n-\n-\n58,343\n570,549\n-\n58,343\n3\n570,549\n1,696\n-182,541\nNeurogastrx(주3)\n-\n2021.06.18\n단순투자\n-\n-\n-\n-\n4,782,095\n4,569,923\n-\n4,782,095\n2\n4,569,923\n10,707\n-3,000\n온코크로스\n비상장\n2021.04.01\n단순투자\n-\n-\n-\n-\n13,214\n1,000,036\n-\n13,214\n1\n1,000,036\n18,708,828\n-12,821,021\n합 계\n-\n-\n205,920,569\n16,759,299\n80,750,023\n-29,646,910\n2,828,048,203\n1,461\xa0\n257,023,682\n1,148,781,929\n-27,531,295\n(주1) 상기 최근사업연도 재무현황은 20년 기말 재무제표 기준입니다.(주2) 3D Matrix의 재무현황 표기 단위는 천엔입니다.(주3)\xa0 Evolus, Nurrron 재무현황 표기 단위는 천달러입니다.(주4) 19년 기말 재무현황입니다.\n* 장부가액 감액 사유\n(단위 : 천원)\n법인명\n감액금액\n감액 사유\nEvolus.INC\n-28,776,629\n시가평가에 따른 공정가치 감소\n힐리언스\xa0\n-1,426,312\n손상평가에 따른 손상액 인식\n']"
